Maximilian Kramer-Drauberg

Maximilian Kramer-Drauberg

Auto-generated profile, based on publicly available information

Maximilian Kramer-Drauberg

Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MKMaximilian Kramer-Drauberg
Maximilian Kramer-Drauberg
JLJu-Ling Liu
Ju-Ling Liu
DDDavid Desjardins
David Desjardins
YWYing Wang
Ying Wang
RBRobyn Branicky
Robyn Branicky
SHSiegfried Hekimi
Siegfried Hekimi
Reactive oxygen species (ROS) are signalling molecules whose study in intact organisms has been hampered by their potential toxicity. This has prevented a full understanding of their role in organismal processes such as development, aging and disease. In Caenorhabditis elegans, the development of the vulva is regulated by a signalling cascade that includes LET-60ras (homologue of mammalian Ras), MPK-1 (ERK1/2) and LIN-1 (an ETS transcription factor). We show that both mitochondrial and cytoplasmic ROS act on a gain-of-function (gf) mutant of the LET-60ras protein through a redox-sensitive cysteine (C118) previously identified in mammals. We show that the prooxidant paraquat as well as isp-1, nuo-6 and sod-2 mutants, which increase mitochondrial ROS, inhibit the activity of LET-60rasgf on vulval development. In contrast, the antioxidant NAC and loss of sod-1, both of which decrease cytoplasmic H202, enhance the activity of LET-60rasgf. CRISPR replacement of C118 with a non-oxidizable serine (C118S) stimulates LET-60rasgf activity, whereas replacement of C118 with aspartate (C118D), which mimics a strongly oxidised cysteine, inhibits LET-60rasgf. These data strongly suggest that C118 is oxidized by cytoplasmic H202 generated from dismutation of mitochondrial and/or cytoplasmic superoxide, and that this oxidation inhibits LET-60ras. This contrasts with results in cultured mammalian cells where it is mostly nitric oxide, which is not found in worms, that oxidizes C118 and activates Ras. Interestingly, PQ, NAC and the C118S mutation do not act on the phosphorylation of MPK-1, suggesting that oxidation of LET-60ras acts on an as yet uncharacterized MPK-1-independent pathway. We also show that elevated cytoplasmic superoxide promotes vulva formation independently of C118 of LET-60ras and downstream of LIN-1. Finally, we uncover a role for the NADPH oxidases (BLI-3 and DUOX-2) and their redox-sensitive activator CED-10rac in stimulating vulva development. Thus, there are at least three genetically separable pathways by which ROS regulates vulval development. Reactive oxygen species (ROS) are signalling molecules whose study in intact organisms has been hampered by their potential toxicity. In Caenorhabditis elegans, the development of the vulva is regulated by a signal transduction cascade that includes LET-60ras (the worm homologue of mammalian RAS), MPK-1 (the worm homologue of ERK1/2), and LIN-1 (an ETS transcription factor). Here, using C. elegans vulva development as a model, we show that both mitochondrial and cytoplasmic ROS act on the worm homologue of RAS (LET-60ras) through a redox-sensitive cysteine (C118). However, in contrast to what is observed in cultured mammalian cells, we find that C118 is oxidized by hydrogen peroxide, rather than by superoxide or nitric oxide, and that its oxidation inhibits rather than activates the pathway. Furthermore, we find that the regulation of LET-60ras by oxidation does not act through MPK-1 to affect vulva development. We also identify two additional ROS signalling pathways that promote vulva development. Elevated cytoplasmic superoxide promotes vulva formation independently of C118 of LET-60ras and downstream of LIN-1, whereas the NADPH oxidases (BLI-3 and DUOX-2) and their redox-sensitive activator CED-10rac act in yet another parallel pathway to promote vulval formation.

2 December 2022 in Science Advances
Verified
Journal Article
Open access
RBRobyn Branicky
Robyn Branicky
YWYing Wang
Ying Wang
AKArman Khaki
Arman Khaki
JLJu-Ling Liu
Ju-Ling Liu
MKMaximilian Kramer-Drauberg
Maximilian Kramer-Drauberg
SHSiegfried Hekimi
Siegfried Hekimi
We show that elevation of mitochondrial superoxide generation increasesCaenorhabditis eleganslife span by enhancing a RAS-dependent ROS (reactive oxygen species) signaling pathway (RDRS) that controls the expression of half of the genome as well as animal composition and physiology. RDRS stimulation mimics a program of change in gene expression that is normally observed at the end of postembryonic development. We further show that RDRS is regulated by negative feedback from the superoxide dismutase 1 (SOD-1)-dependent conversion of superoxide into cytoplasmic hydrogen peroxide, which, in turn, acts on a redox-sensitive cysteine (C118) of RAS. Preventing C118 oxidation by replacement with serine, or mimicking oxidation by replacement with aspartic acid, leads to opposite changes in the expression of the same large set of genes that is affected when RDRS is stimulated by mitochondrial superoxide. The identities of these genes suggest that stimulation of the pathway extends life span by boosting turnover and repair while moderating damage from metabolic activity.

12 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
MKMaximilian Kramer-Drauberg
Maximilian Kramer-Drauberg
RGRósula García-Navas
Rósula García-Navas
EPEnrico Patrucco
Enrico Patrucco
EPEttore Petrini
Ettore Petrini
Eugenio SantosEugenio Santos
Eugenio Santos
We evaluated the in vivo therapeutic efficacy and tolerability of BI-3406-mediated pharmacological inhibition of SOS1 in comparison to genetic ablation of this universal Ras-GEF in various KRAS-dependent experimental tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2 KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. Allograft assays using different KRAS mut cell lines showed that treatment with BI-3406 impaired RAS activation and RAS downstream signaling and decreased tumor burden and disease progression as a result of both tumor-intrinsic and -extrinsic therapeutic effects of the drug. Consistent with prior genetic evidence and the KRAS mut allografts assays in immunocompromised mice, our analyses using an in vivo model of KRAS G12D -driven lung adenocarcinoma (LUAD) in immunocompetent mice showed that single, systemic BI-3406 treatment impaired tumor growth and downmodulated protumorigenic components of the tumor microenvironment comparably to SOS1 genetic ablation or to treatment with the specific KRAS G12D inhibitor MRTX1133. Furthermore, markedly stronger, synergistic antitumor effects were observed upon concomitant treatment with BI-3406 and MRTX1133 in the same in vivo LUAD mouse model. Our data confirm SOS1 as an actionable therapy target in RAS-dependent cancers and suggest that BI-3406 treatment may yield clinical benefit both as monotherapy or as a potential combination partner for multiple RAS-targeting strategies.

22 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FBFERNANDO CALVO BALTANAS
FERNANDO CALVO BALTANAS
MKMaximilian Kramer-Drauberg
Maximilian Kramer-Drauberg
RGRosula García-Navas
Rosula García-Navas
EPEnrico Patrucco
Enrico Patrucco
EPEttore Petrini
Ettore Petrini
Eugenio SantosEugenio Santos
Eugenio Santos
Resistance to KRAS mut inhibitors frequently arises, warranting further searches for anti-RAS cancer therapies. We evaluated the tolerability and efficacy of SOS1 pharmacological inhibition in comparison to genetic ablation in different KRAS-dependent tumor settings. Contrary to the rapid lethality caused by SOS1 genetic ablation in SOS2KO mice, SOS1 pharmacological inhibition by its specific inhibitor BI-3406 did not significantly affect animal weight/viability nor cause noteworthy systemic toxicity. In BI-3406-treated KRAS mut MEFs, we observed significantly reduced RAS-GTP levels and RAS downstream signaling, as well as decreased tumor burden and slower disease progression resulting from tumor-intrinsic and extrinsic therapeutic drug effects. In vivo analyses of KRAS G12D allografts in immunocompromised mice and KRAS G12D -driven lung adenocarcinomas in immunocompetent mice showed that systemic BI-3406 treatment impaired tumor growth and downmodulated components of the tumor microenvironment comparably to the KRAS G12D inhibitor MRTX1133. Markedly stronger synergistic antitumor effects were observed upon concomitant BI-3406+MRTX113 treatment, confirming SOS1 as an actionable therapy target in RAS-dependent cancers.